Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion type Assertion NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_head.
- NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion description "[However, a significant fraction of patients with HER2+ breast cancer treated with these agents eventually relapse or develop progressive disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_provenance.
- NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion evidence source_evidence_literature NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_provenance.
- NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion SIO_000772 22471661 NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_provenance.
- NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion wasDerivedFrom befree-2016 NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_provenance.
- NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_assertion wasGeneratedBy ECO_0000203 NP972214.RA41EAnEhqEjvwQupD8e0zF4l6DtwyjlxffSZda1qX7kM130_provenance.